Evidence map›Paper›PMID 31916456›Full record

ArticleFuture medicinal chemistry2020

Vasilichia Antoci, Dumitrela Cucu, Gheorghita Zbancioc, Costel Moldoveanu, Violeta Mangalagiu, Dorina Amariucai-Mantu, Aculina Aricu, Ionel I Mangalagiu

Abstract read
In one paragraph

Article in Future medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Article
  5. HybridPharmaceuticals (Basel, Switzerland) · 2025
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Hybrid Quinoline-Sulfonamide Complexes (MMolecules (Basel, Switzerland) · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Vasilichia AntociFaculty of Chemistry, Alexandru Ioan Cuza University of Iasi, 11 Carol I Bd, Iasi 700506, Romania.
Dumitrela CucuFaculty of Chemistry, Alexandru Ioan Cuza University of Iasi, 11 Carol I Bd, Iasi 700506, Romania.
Gheorghita ZbanciocFaculty of Chemistry, Alexandru Ioan Cuza University of Iasi, 11 Carol I Bd, Iasi 700506, Romania.
Costel MoldoveanuFaculty of Chemistry, Alexandru Ioan Cuza University of Iasi, 11 Carol I Bd, Iasi 700506, Romania.
Violeta MangalagiuInterdisciplinary Research Institute - CERNESIM Center, Alexandru Ioan Cuza University of Iasi, 11 Carol I Bd, Iasi 700506, Romania.
Dorina Amariucai-MantuFaculty of Chemistry, Alexandru Ioan Cuza University of Iasi, 11 Carol I Bd, Iasi 700506, Romania.
Aculina AricuInstitute of Chemistry, Academiei Street 3, 2028 Chisinau, Moldova.
Ionel I MangalagiuFaculty of Chemistry, Alexandru Ioan Cuza University of Iasi, 11 Carol I Bd, Iasi 700506, Romania.ORCID 0000-0002-4632-5076

Funding

NIAID NIH HHS HHSN272201100009INIAID NIH HHS HHSN272201100019I
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Anti-Bacterial AgentsBenzimidazolesHumansImidazolesMicrobial Sensitivity TestsMycobacterium tuberculosisPyridinesTuberculosisAnti-Bacterial AgentsbenzimidazoleBenzimidazolesimidazoleImidazolespyridinePyridinesADMETantimycobacterialbis-(imidazole/benzimidazole)-pyridineMBCMIC

Identifiers

PMID31916456
PMCPMC7421780

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.